(Q30697695)

26 June 2017

1 reference

title

Implications of lipid biology for the pathogenesis of schizophrenia (English)

1 reference

26 June 2017

0 references

1 reference

R Mark Wellard

5

0 references

Stephen J Wood

object named as

Stephen J Wood

series ordinal

2

0 references

Christos Pantelis

series ordinal

3

object named as

Christos Pantelis

1 reference

26 June 2017

6

Patrick D McGorry

1 reference

26 June 2017

Gregor E Berger

1

1 reference

26 June 2017

Dennis Velakoulis

series ordinal

4

1 reference

26 June 2017

publication date

1 June 2002

1 reference

Australian and New Zealand Journal of Psychiatry

26 June 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 June 2017

volume

36

1 reference

26 June 2017

issue

3

1 reference

26 June 2017

page(s)

355-366

1 reference

Determination of fatty acids in cerebrospinal fluid. V. The fatty acid content in the total lipids of cerebrospinal fluid in psychiatric patients.

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Erythrocyte membrane phospholipids in psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Histamine and prostaglandins in schizophrenia: revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

The membrane hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Neuropsychiatric aspects of the adult variant of Tay-Sachs disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Neuroprotection by estradiol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Bioactive lipids in excitatory neurotransmission and neuronal plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Schizophrenia as a disorder of developmentally reduced synaptic connectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

The role of cannabinoids in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Neonatal polyunsaturated fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

The Nithsdale Schizophrenia Surveys. 16. Breast-feeding and schizophrenia: preliminary results and hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Fat consumption and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Fish consumption and depressive symptoms in the general population in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Schizophrenia as a prostaglandin deficiency disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

At issue: schizophrenia and rheumatoid arthritis: the negative association revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Fatty acid levels in the brains of schizophrenics and normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

The expanding superfamily of phospholipase A(2) enzymes: classification and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Phospholipase A2 and the hypofrontality hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Increased platelet phospholipase A2 activity in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Elevated PLA2 activity in schizophrenics and other psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Genetic variant near cytosolic phospholipase A2 associated with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Lack of association between schizophrenia and the phospholipase-A(2) genes cPLA2 and sPLA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Volatile organic compounds in the breath of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Quantifying 1H decoupled in vivo 31P brain spectra

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Magnetic resonance spectroscopy and schizophrenia: what have we learnt?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings--part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Phosphorus 31 Magnetic Resonance Spectroscopy Detects Altered Brain Metabolism Before Onset of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Quantitative proton-decoupled 31P MRS of the schizophrenic brain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Changes in dietary fatty acids alter phospholipid fatty acid composition in selected regions of rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Postprocessing method to segregate and quantify the broad components underlying the phosphodiester spectral region of in vivo (31)P brain spectra

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

31P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Initial investigation of the left temporoparietal region in schizophrenia by 31P magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

High-energy phosphates in the frontal lobe correlate with Wisconsin Card Sort Test performance in controls, not in schizophrenics: a 31phosphorus magnetic resonance spectroscopic and neuropsychological investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics--a study including 50 patients and 36 controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

An imbalance of dietary essential fatty acids retards behavioral development in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

n-3 and n-6 fatty acid enrichment by dietary fish oil and phospholipid sources in brain cortical areas and nonneural tissues of formula-fed piglets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Effects of dietary n-3 fatty acids on the phospholipid molecular species of monkey brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Clinical and biochemical correlates of "high-dose" clozapine therapy for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

No association between breast-feeding and adult psychosis in two national birth cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1614.2001.01021.X

10.1046/J.1440-1614.2001.01021.X

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference